NNE1

NNE1

File:NNEI structure.png
Systematic (IUPAC) name
N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide
Clinical data
Legal status	CA: Schedule II
Identifiers
CAS Number	1338925-11-3
PubChem	CID: 54752945
ChemSpider	26613275
UNII	7FVT9P642K Y
Chemical data
Formula	C24H24N2O
Molecular mass	356.47 g/mol
SMILES CCCCCn1cc(c2c1cccc2)C(=O)Nc1cccc2c1cccc2
InChI InChI=1S/C24H24N2O/c1-2-3-8-16-26-17-21(20-13-6-7-15-23(20)26)24(27)25-22-14-9-11-18-10-4-5-12-19(18)22/h4-7,9-15,17H,2-3,8,16H2,1H3,(H,25,27) Key:GWCQNKRMTGVYIZ-UHFFFAOYSA-N

NNE1 (also known as NNEI, MN-24 and AM-6527) is an indole-based synthetic cannabinoid, representing a molecular hybrid of APICA and JWH-018. It was invented by Abbott and has a CB₁ receptor pEC₅₀ of 8.9 (i.e. EC₅₀ of approximately 1nM) with around 80x selectivity over the related CB₂ receptor. It is suspected that metabolic hydrolysis of the amide group of NNE1 may release 1-naphthylamine, a known carcinogen, given the known metabolic liberation (and presence as an impurity) of amantadine in the related compound APINACA, and NNE1 was banned in New Zealand in 2012 as a temporary class drug to stop it being used as an ingredient in then-legal synthetic cannabis products. NNE1 was subsequently found to be responsible for the death of a man in Japan in 2014.

See also

• 5F-NNE1
• 5F-PCN
• AM-2201
• APICA
• CUMYL-PICA
• FDU-NNE1
• JWH-018
• NM-2201
• SDB-005